Skip to main content

Advertisement

SpringerLink
Log in

The New Kid on the Block—Incorporating Buprenorphine into a Medical Toxicology Practice

  • Proceedings
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

Buprenorphine represents a safe and effective therapy for treating opioid dependence, alleviating craving and withdrawal symptoms in opioid-dependent patients. Buprenorphine has a “blocking” effect against the action of other opioids at the mu-receptor, preventing not only opioid-induced euphoria, but CNS and respiratory depressant effects as well. Buprenorphine was approved for the treatment of opioid dependence in 2002 after the passage of Drug Abuse Treatment Act 2000 (DATA 2000) which allowed clinicians to treat opioid-dependent patients with specifically named opioid agonist therapies in an office setting. Buprenorphine programs reduce the prevalence of HIV and hepatitis C and reduce criminal behaviors associated with illicit drug use. Patients stabilized on buprenorphine have increased employment, enhanced engagement with social services, and better overall health and well-being.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ling W, Mooney L, Torrington M. Buprenorphine for opioid addiction. Pain Management. 2012;2(4):345–50.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med. 2004;43(5):580–4.

    Article  PubMed  Google Scholar 

  3. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs. 2006;20(9):697–712.

    Article  CAS  PubMed  Google Scholar 

  4. Control, U.S.D.o.J.O.o.D. Title 21 Code of Federal Regulations Part 1306: Prescriptions. 2015 [cited 2015 7/18/2015].

  5. Pergolizzi J et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–50.

    Article  PubMed  Google Scholar 

  6. Karp JF et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Induru RR, Davis MP. Buprenorphine for neuropathic pain—targeting hyperalgesia. Am J Hosp Palliat Care. 2009;26(6):470–3.

    Article  PubMed  Google Scholar 

  8. Kouya PF, Hao JX, Xu XJ. Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol. 2002;450(1):49–53.

    Article  CAS  PubMed  Google Scholar 

  9. Daitch D et al. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087–94.

    Article  PubMed  Google Scholar 

  10. Mendelson J et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37(1):31–7.

    Article  CAS  PubMed  Google Scholar 

  11. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661–80.

    Article  CAS  PubMed  Google Scholar 

  12. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. REMS, B.T.f.O.D. BTOD/REMS. 2015 [cited 2015 7/15/2015].

  14. Inc, R.B.P. Suboxone(R) Sublingual Film. 2015 [cited 2015 6/30/2015]; Available from: http://www.suboxone.com/.

  15. Pharmaceuticals, O. Zubsolv Sublingual Films. 2015 [cited 2015 8/1/2015]; Available from: https://www.zubsolv.com/.

  16. Biodelivery Sciences International, I. Bunivail buccal film. 2015 [cited 2015 8/5/2015].

  17. Colameco S, Pohl M. Buprenorphine in the workers’ compensation setting. J Opioid Manag. 2014;10(4):277–83.

    Article  PubMed  Google Scholar 

  18. Administration, S.A.a.M.H.S. Buprenorphine. 2012 [cited 2015 8/10/2015]; Available from: http://buprenorphine.samhsa.gov/about.html.

  19. Greene, P., Outpatient drug utilization trends for buprenorphine years 2002-2009, D.o.E.O.o.S.a.E.U.S.F.a.D. Administration, Editor. 2010, U.S. Food and Drug Administration.

  20. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-9.

  21. Administration, S.A.a.M.H.S. Buprenorphine. 2012 [cited 2015 8/5/2015]; Available from: http://buprenorphine.samhsa.gov/about.html.

  22. Lee JD et al. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24(2):226–32.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Cunningham CO et al. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat. 2011;40(4):349–56.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Fiellin DA et al. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27(2):153–9.

    Article  PubMed  Google Scholar 

  25. Centers for Disease, C. and Prevention. HIV infection among injection-drug users—34 states, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009;58(46):1291–5.

    Google Scholar 

  26. Conrad C et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4.

    PubMed  Google Scholar 

  27. Sullivan LE et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87–92.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Rosado J et al. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend. 2007;90(2-3):261–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Clark NC, Lintzeris N, Muhleisen PJ. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Med J Aust. 2002;176(4):166–7.

    PubMed  Google Scholar 

  30. Lovegrove MC et al. Emergency hospitalizations for unsupervised prescription medication ingestions by young children. Pediatrics. 2014;134(4):e1009–16.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kim HK et al. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics. 2012;130(6):e1700–3.

    Article  PubMed  Google Scholar 

  32. Dasgupta N et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010;11(7):1078–91.

    Article  PubMed  Google Scholar 

  33. Gwin Mitchell S et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18(5):346–55.

    Article  PubMed  Google Scholar 

  34. Cicero TJ, Surratt H, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3(6):302–8.

    PubMed  Google Scholar 

  35. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–19.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Emergency Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

    Timothy J. Wiegand

Authors
  1. Timothy J. Wiegand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy J. Wiegand.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wiegand, T.J. The New Kid on the Block—Incorporating Buprenorphine into a Medical Toxicology Practice. J. Med. Toxicol. 12, 64–70 (2016). https://doi.org/10.1007/s13181-015-0518-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-015-0518-4

Keywords

Search

Navigation